Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: vincristine sulfate

« Back to Dashboard
Vincristine sulfate is the generic ingredient in six branded drugs marketed by Talon Therap, Lilly, Teva Parenteral, Bristol Myers Squibb, Abic, Abraxis Pharm, Fresenius Kabi Usa, Hospira, and Teva Pharms Usa, and is included in thirteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has forty-seven patent family members in fifteen countries.

There are twelve drug master file entries for vincristine sulfate. One supplier is listed for this compound.

Summary for Generic Name: vincristine sulfate

Tradenames:6
Patents:3
Applicants:9
NDAs:13
Drug Master File Entries: see list12
Suppliers: see list1
Formulation / Manufacturing:see details

Clinical Trials for: vincristine sulfate

Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia
Status: Recruiting Condition: Adult Acute Lymphoblastic Leukemia

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Status: Terminated Condition: Acute Leukemias of Ambiguous Lineage; Acute Undifferentiated Leukemia; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Relapsing Chronic Myelogenous Leukemia; Small Intestine Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm
VINCRISTINE SULFATE
vincristine sulfate
INJECTABLE;INJECTION070411-001Sep 10, 1986DISCNNo<disabled><disabled>
Hospira
VINCRISTINE SULFATE
vincristine sulfate
INJECTABLE;INJECTION071560-001Apr 11, 1988DISCNNo<disabled><disabled>
Lilly
ONCOVIN
vincristine sulfate
INJECTABLE;INJECTION014103-001Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
Hospira
VINCRISTINE SULFATE
vincristine sulfate
INJECTABLE;INJECTION071559-001Apr 11, 1988DISCNNo<disabled><disabled>
Teva Parenteral
VINCASAR PFS
vincristine sulfate
INJECTABLE;INJECTION071426-001Jul 17, 1987DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: vincristine sulfate

Country Document Number Publication Date
Japan2012092148May 17, 2012
World Intellectual Property Organization (WIPO)0203745Jan 10, 2002
Israel212390Jun 30, 2011
World Intellectual Property Organization (WIPO)0203612Jun 06, 2002
Israel212390Aug 31, 2014
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc